{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:35:14Z","timestamp":1771014914698,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,3,2]],"date-time":"2014-03-02T00:00:00Z","timestamp":1393718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>On the basis of two population\u2010based registries, our study aims to calculate the real\u2010world cost\u2010effectiveness of rituximab maintenance compared with observation in relapsed or refractory follicular lymphoma patients who responded to second\u2010line chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were obtained from the <jats:styled-content style=\"fixed-case\">EORTC<\/jats:styled-content>20981 trial, the Netherlands Cancer Registry and two population\u2010based registries. A Markov model was developed to calculate cost per life year gained (<jats:styled-content style=\"fixed-case\">LYG<\/jats:styled-content>) and quality\u2010adjusted life years (<jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content>s) for three scenarios.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our real\u2010world patients were (62\u00a0years) 6 to 7\u00a0years older and had higher complete response rates to second\u2010line chemotherapy than the trial population. Differences between the real\u2010world rituximab and observation group were observed for second\u2010line chemotherapy and disease progression. Groups were more balanced after using propensity matching. Relying entirely on updated trial results (<jats:italic>scenario1<\/jats:italic>) in combination with local cost data resulted in ratios of \u20ac11\u00a0259 per <jats:styled-content style=\"fixed-case\">LYG<\/jats:styled-content> and \u20ac12\u00a0655 per <jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content>. For <jats:italic>scenario2<\/jats:italic>, consisting of trial efficacy and matched real\u2010world costs, ratios of \u20ac21\u00a0202 per <jats:styled-content style=\"fixed-case\">LYG<\/jats:styled-content> and \u20ac23\u00a0821 per <jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content> were calculated. Using real\u2010world matched evidence (<jats:italic>scenario3<\/jats:italic>) for both effectiveness and costs showed ratios of \u20ac10\u00a0591 per <jats:styled-content style=\"fixed-case\">LYG<\/jats:styled-content> and \u20ac11\u00a0245 per <jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although differences in real\u2010world and trial population were found, using real\u2010world data as well as results from long\u2010term trial follow\u2010up showed favourable <jats:styled-content style=\"fixed-case\">ICER<\/jats:styled-content>s for rituximab maintenance. Nevertheless, results showed that caution is required with data synthesis, interpretation and generalisability of results. As different scenarios provide answers to different questions, we recommend healthcare decision\u2010makers to recognise the importance of calculating several cost\u2010effectiveness scenarios.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12264","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T08:42:41Z","timestamp":1389256961000},"page":"398-406","source":"Crossref","is-referenced-by-count":16,"title":["Cost\u2010effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population\u2010based study"],"prefix":"10.1111","volume":"92","author":[{"given":"Hedwig M.","family":"Blommestein","sequence":"first","affiliation":[{"name":"Department of Health Policy &amp; Management Institute for Medical Technology Assessment Erasmus University Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djamila E.","family":"Issa","sequence":"additional","affiliation":[{"name":"VU University Medical Center Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Pompen","sequence":"additional","affiliation":[{"name":"Roche Pharmaceuticals Woerden The Netherlands"},{"name":"Currently employed at Bristol\u2010Myers Squibb Woerden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Ten Hoor","sequence":"additional","affiliation":[{"name":"Roche Pharmaceuticals Woerden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mels","family":"Hogendoorn","sequence":"additional","affiliation":[{"name":"Medical Center Leeuwarden Leeuwarden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Joosten","sequence":"additional","affiliation":[{"name":"Medical Center Leeuwarden Leeuwarden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"VU University Medical Center Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Huijgens","sequence":"additional","affiliation":[{"name":"VU University Medical Center Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin A.","family":"Uyl\u2010de Groot","sequence":"additional","affiliation":[{"name":"Department of Health Policy &amp; Management Institute for Medical Technology Assessment Erasmus University Rotterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00186.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.010"},{"key":"e_1_2_9_14_1","first-page":"321","article-title":"A \u2018population based registry\u2019 for hemato\u2010oncology","volume":"7","author":"Huijgens PC","year":"2010","journal-title":"Nederlands Tijdschrift voor Hematologie"},{"key":"e_1_2_9_15_1","first-page":"104","article-title":"HemoBase: an intelligent electronic patient file as aid for hemato\u2010onocology care","volume":"6","author":"Hoogendoorn M","year":"2009","journal-title":"Nederlands Tijdschrift voor Hematologie"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_9_17_1","volume-title":"Handleiding voor kostenonderzoek: Methoden en referentieprijzen voor economische evaluaties in de gezondheidszorg","author":"Tan S","year":"2010"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)63491-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903149479"},{"key":"e_1_2_9_20_1","volume-title":"Guidance for Outcomes Research for the Assessment of the Costeffectiveness of In\u2010Patient Medicines","author":"Delwel GO","year":"2008"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/11314070-000000000-00000"},{"key":"e_1_2_9_22_1","first-page":"163","article-title":"Cost\u2010effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line","volume":"86","author":"Castro Gomez AJ","year":"2012","journal-title":"Rev Esp Salud Publica"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2109"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802120028"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12264","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:59:30Z","timestamp":1695473970000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,2]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/ejh.12264"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12264","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,2]]}}}